Who are SCH 39641's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Singulair, Accolate, Montelukast (Low FeNO group), MK0476; montelukast sodium, Comparator: Montelukast, montelukast and cetirizine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sch-39641.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

SCH 39641 — Competitive Intelligence Brief

SCH 39641 (SCH 39641) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene receptor antagonist. Area: Immunology / Respiratory.

phase 3 Leukotriene receptor antagonist Cysteinyl leukotriene receptors (CysLT1/CysLT2) Immunology / Respiratory Biologic Live · refreshed every 30 min

Target snapshot

SCH 39641 (SCH 39641) — ALK-Abelló A/S. SCH 39641 is a leukotriene receptor antagonist that blocks cysteinyl leukotriene receptors to reduce inflammatory responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SCH 39641 TARGET	SCH 39641	ALK-Abelló A/S	phase 3	Leukotriene receptor antagonist	Cysteinyl leukotriene receptors (CysLT1/CysLT2)
Singulair	montelukast	Merck & Co.	marketed	Leukotriene receptor antagonist (LTRA)	Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2	1998-02-20
Accolate	ZAFIRLUKAST	Strides Pharma Intl	marketed	Leukotriene Receptor Antagonist [EPC]	Cysteinyl leukotriene receptor 1	1996-01-01
Montelukast (Low FeNO group)	Montelukast (Low FeNO group)	Hull University Teaching Hospitals NHS Trust	marketed	Leukotriene receptor antagonist	CysLT1 (cysteinyl leukotriene receptor type 1)
MK0476; montelukast sodium	MK0476; montelukast sodium	Organon and Co	marketed	Cysteinyl leukotriene receptor antagonist (LTRA)	CysLT1 (cysteinyl leukotriene receptor 1)
Comparator: Montelukast	Comparator: Montelukast	Organon and Co	marketed	Cysteinyl leukotriene receptor antagonist (LTRA)	CysLT1 (cysteinyl leukotriene receptor 1)
montelukast and cetirizine	montelukast and cetirizine	Medical University of Lodz	marketed	Leukotriene receptor antagonist and H1-receptor antagonist combination	CysLT1 receptor (montelukast); H1 histamine receptor (cetirizine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene receptor antagonist class)

Organon and Co · 2 drugs in this class
Hull University Teaching Hospitals NHS Trust · 2 drugs in this class
ALK-Abelló A/S · 1 drug in this class
King Abdullah International Medical Research Center · 1 drug in this class
SamA Pharmaceutical Co., Ltd · 1 drug in this class
Kecioren Education and Training Hospital · 1 drug in this class
GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SCH 39641 — Competitive Intelligence Brief. https://druglandscape.com/ci/sch-39641. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab